Driss Raissi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Driss Raissi has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Michael A. Winkler
Department of Mathematical Optimization Zuse Institute Berlin Takustr. 7 14195 Berlin
6 shared publications Qiong Han
Department of Radiology, University of Kentucky, 800 Rose Street HX315E, Lexington, KY 40506 USA
6 shared publicationsQian Yu
Department of Radiology, Medicine and Obstetrics and Gynecology, University of Kentucky, College of Medicine, Lexington, United States
4 shared publications- Amie Goodin
Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, FL, USA
3 shared publications - Gaby Gabriel
Department of Radiology, Division of Vascular and Interventional Radiology, University of Kentucky College of Medicine, 780 Rose Street, Lexington, KY 40506, USA
3 shared publications - Jack Bailey Newcomer
Mayo Clinic Department of Dermatology Rochester Minnesota USA
3 shared publications
Latest Publications
- Open Access
- 13 February 2024
- Published by Scientific Scholar in Journal of Clinical Imaging Science
- Vol. 14, 4
Percutaneous microwave ablation for early-stage intrahepatic cholangiocarcinoma: A single-institutional cohort
Objectives: Cholangiocarcinoma (CCA) is the second-most common primary hepatic malignancy with an increasing incidence over the past two decades. CCA arises from the epithelial cells lining the bile ducts and can be classified as intrahepatic, perihilar, or distal based on the site of origin in the biliary tree. Surgical resection is the definitive curative therapy for early-stage intrahepatic CCA; however, only a minority of patients may be ideal surgical candidates. Percutaneous microwave ablation (MWA) is a minimally invasive procedure widely used for hepatocellular carcinoma and colorectal cancer metastases to the liver. Growing evidence suggests MWA can play a role in the management of patients with early-stage intrahepatic CCA. In this study, we aim to describe the safety and efficacy of MWA for the management of intrahepatic CCA. Material and Methods: A retrospective review of patients with intrahepatic CCA treated with MWA at our tertiary referral medical center was performed. Eight patients were treated between 2014 and 2019. Diagnosis of CCA was made based on histopathological studies of samples obtained by surgical resection or percutaneous liver biopsy. All procedures were performed under computed tomography (CT) guidance using a high-power single antenna MWA system. General anesthesia was used for all procedures. Patient medical history, procedural technical information, outcomes, and follow-up data were reviewed. Progression-free survival was estimated with a Kaplan–Meier curve. Results: A total of 25 tumors with an average size of 2.2 ± 1.7 cm (range 0.5–7.8) were treated with MWA. Our cohort consisted of eight patients (4 males and 4 females) with an average age of 69.3 ± 5.7 years (range 61–79). Three out of eight (3/8, 37.5%) patients were treated initially with surgical resection. NASH-related cirrhosis was documented in 3/8 (37.5%) patients, while 1/8 (12.5%) had alcoholic cirrhosis; the remaining 4 patients (4/8, 50%) did not have cirrhosis. All patients were discharged within 24 h after ablation. Average total follow-up time was 10.6 ± 11.8 months (range 0–41). The incomplete ablation rate and local recurrence rate were 4% (1/25 lesions) and 12% (3/25 lesions), respectively. Conclusion: In patients who do not qualify for surgical resection, MWA is a safe alternative therapy for the treatment of intrahepatic CCA.
- 13 February 2024
- Published by Scientific Scholar in Journal of Clinical Imaging Science
- Vol. 14, 4
Open AccessPercutaneous microwave ablation for early-stage intrahepatic cholangiocarcinoma: A single-institutional cohort
Objectives: Cholangiocarcinoma (CCA) is the second-most common primary hepatic malignancy with an increasing incidence over the past two decades. CCA arises from the epithelial cells lining the bile ducts and can be classified as intrahepatic, perihilar, or distal based on the site of origin in the biliary tree. Surgical resection is the definitive curative therapy for early-stage intrahepatic CCA; however, only a minority of patients may be ideal surgical candidates. Percutaneous microwave ablation (MWA) is a minimally invasive procedure widely used for hepatocellular carcinoma and colorectal cancer metastases to the liver. Growing evidence suggests MWA can play a role in the management of patients with early-stage intrahepatic CCA. In this study, we aim to describe the safety and efficacy of MWA for the management of intrahepatic CCA. Material and Methods: A retrospective review of patients with intrahepatic CCA treated with MWA at our tertiary referral medical center was performed. Eight patients were treated between 2014 and 2019. Diagnosis of CCA was made based on histopathological studies of samples obtained by surgical resection or percutaneous liver biopsy. All procedures were performed under computed tomography (CT) guidance using a high-power single antenna MWA system. General anesthesia was used for all procedures. Patient medical history, procedural technical information, outcomes, and follow-up data were reviewed. Progression-free survival was estimated with a Kaplan–Meier curve. Results: A total of 25 tumors with an average size of 2.2 ± 1.7 cm (range 0.5–7.8) were treated with MWA. Our cohort consisted of eight patients (4 males and 4 females) with an average age of 69.3 ± 5.7 years (range 61–79). Three out of eight (3/8, 37.5%) patients were treated initially with surgical resection. NASH-related cirrhosis was documented in 3/8 (37.5%) patients, while 1/8 (12.5%) had alcoholic cirrhosis; the remaining 4 patients (4/8, 50%) did not have cirrhosis. All patients were discharged within 24 h after ablation. Average total follow-up time was 10.6 ± 11.8 months (range 0–41). The incomplete ablation rate and local recurrence rate were 4% (1/25 lesions) and 12% (3/25 lesions), respectively. Conclusion: In patients who do not qualify for surgical resection, MWA is a safe alternative therapy for the treatment of intrahepatic CCA.
- Open Access
- 26 June 2023
- Published by Scientific Scholar in Journal of Clinical Imaging Science
- Vol. 13, 18
Transjugular intrahepatic portosystemic shunt for pediatric portal hypertension: A meta-analysis
To evaluate the feasibility of transjugular intrahepatic portosystemic shunt (TIPS) in children with portal hypertensive complications, PubMed and Cochrane Library were queried to identify clinical studies evaluating TIPS in patients <18 years old. Baseline clinical characteristics, laboratory values, and clinical outcomes were extracted. Eleven observational studies totaling 198 subjects were included in the study. The pooled technical success rate and hemodynamic success rate were 94% (95% confidence interval [CI]: 86–99%) and 91% (95% CI: 82–97%), respectively; ongoing variceal bleeding resolved in 99.5% (95% CI: 97–100%); refractory ascites was improved in 96% (95% CI: 69–100%); post-TIPS bleeding rate was 14% (95% CI: 1–33%); 88% of patients were alive or successfully received liver transplant (95% CI: 79–96%); and shunt dysfunction rate was 27% (95% CI: 17–38%). Hepatic encephalopathy occurred in 10.6% (21/198), though 85.7% (18/21) resolved with medical management only. In conclusion, based on moderate levels of evidence, TIPS is a safe and effective intervention that should be considered in pediatric patients with portal hypertensive complications. Future comparative studies are warranted.
- 26 June 2023
- Published by Scientific Scholar in Journal of Clinical Imaging Science
- Vol. 13, 18
Open AccessTransjugular intrahepatic portosystemic shunt for pediatric portal hypertension: A meta-analysis
To evaluate the feasibility of transjugular intrahepatic portosystemic shunt (TIPS) in children with portal hypertensive complications, PubMed and Cochrane Library were queried to identify clinical studies evaluating TIPS in patients <18 years old. Baseline clinical characteristics, laboratory values, and clinical outcomes were extracted. Eleven observational studies totaling 198 subjects were included in the study. The pooled technical success rate and hemodynamic success rate were 94% (95% confidence interval [CI]: 86–99%) and 91% (95% CI: 82–97%), respectively; ongoing variceal bleeding resolved in 99.5% (95% CI: 97–100%); refractory ascites was improved in 96% (95% CI: 69–100%); post-TIPS bleeding rate was 14% (95% CI: 1–33%); 88% of patients were alive or successfully received liver transplant (95% CI: 79–96%); and shunt dysfunction rate was 27% (95% CI: 17–38%). Hepatic encephalopathy occurred in 10.6% (21/198), though 85.7% (18/21) resolved with medical management only. In conclusion, based on moderate levels of evidence, TIPS is a safe and effective intervention that should be considered in pediatric patients with portal hypertensive complications. Future comparative studies are warranted.
- Open Access
- 1 December 2022
- Published by Scientific Scholar in Journal of Clinical Imaging Science
- Vol. 12, 61
Current perspectives on microwave ablation of liver lesions in difficult locations
Microwave ablation (MWA) is becoming the standard of care in treating liver lesions smaller than 3 cm benefiting from a plethora of radiofrequency ablation (RFA) data in the literature. Some of the advantages of MWA compared to RFA are as follows: Faster ablations, more reproducible and predictable heating, better thermal conductivity in different liver tissue environments, and less susceptibility to heat-sink effect. Despite its many advantages, there are still concerns regarding MWA use in high-risk locations such as near portal veins, near the bile ducts, and near the heart. Some centers have historically considered these tumor locations as a contraindication to percutaneous thermal ablation. In this review, we summarize the current data on the safety of MWA of liver tumors in challenging locations. We also discuss several technical tips with examples provided.
- 1 December 2022
- Published by Scientific Scholar in Journal of Clinical Imaging Science
- Vol. 12, 61
Open AccessCurrent perspectives on microwave ablation of liver lesions in difficult locations
Microwave ablation (MWA) is becoming the standard of care in treating liver lesions smaller than 3 cm benefiting from a plethora of radiofrequency ablation (RFA) data in the literature. Some of the advantages of MWA compared to RFA are as follows: Faster ablations, more reproducible and predictable heating, better thermal conductivity in different liver tissue environments, and less susceptibility to heat-sink effect. Despite its many advantages, there are still concerns regarding MWA use in high-risk locations such as near portal veins, near the bile ducts, and near the heart. Some centers have historically considered these tumor locations as a contraindication to percutaneous thermal ablation. In this review, we summarize the current data on the safety of MWA of liver tumors in challenging locations. We also discuss several technical tips with examples provided.
- Open Access
- 1 June 2022
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 11  (3) , 453-456
Editorial comment: a review on radiofrequency, microwave and high-intensity focused ultrasound ablations for hepatocellular carcinoma with cirrhosis
Editorial Editorial comment: a review on radiofrequency, microwave and high-intensity focused ultrasound ablations for hepatocellular carcinoma with cirrhosis Merve Ozen, Driss Raissi
- 1 June 2022
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 11  (3) , 453-456
Open AccessEditorial comment: a review on radiofrequency, microwave and high-intensity focused ultrasound ablations for hepatocellular carcinoma with cirrhosis
Editorial Editorial comment: a review on radiofrequency, microwave and high-intensity focused ultrasound ablations for hepatocellular carcinoma with cirrhosis Merve Ozen, Driss Raissi
- Open Access
- 19 March 2022
- Published by Elsevier in Radiology Case Reports
- Vol. 17  (5) , 1631-1633
Non–surgical management of abdominal ectopic pregnancy with uterine artery embolization
- 19 March 2022
- Published by Elsevier in Radiology Case Reports
- Vol. 17  (5) , 1631-1633
Open AccessNon–surgical management of abdominal ectopic pregnancy with uterine artery embolization
- Open Access
- 2 March 2022
- Published by Elsevier in Radiology Case Reports
- Vol. 17  (5) , 1464-1469
Combined transhepatic and transjugular approach for mechanical thrombectomy of massive TIPS thrombosis
- 2 March 2022
- Published by Elsevier in Radiology Case Reports
- Vol. 17  (5) , 1464-1469
Open AccessCombined transhepatic and transjugular approach for mechanical thrombectomy of massive TIPS thrombosis
- Open Access
- 20 January 2022
- Published by Scientific Scholar in Journal of Clinical Imaging Science
- Vol. 12, 1-7
CT-guided microwave ablation of hepatic malignancies via transpulmonary approach without ancillary techniques
Objectives: The objectives of the study were to determine the safety and efficacy of computed tomography (CT)guided transpulmonary percutaneous microwave ablation (MWA) for hepatic malignancies without the use of ancillary techniques. Material and Methods: A retrospective review was performed on patients who underwent MWA for hepatic malignancy between January 2014 and February 2020 at a single tertiary center. Imaging was reviewed for each procedure to identify MWA showing transpleural transgression on CT scans. For these patients, demographics, ablation data, pulmonary complication rate, and predictors of pneumothorax were analyzed. Results: A total of 71 consecutive sessions (62.1 +/- 11.3 years, 79% of males) of MWA were performed to treat 71 tumors (1.90 +/- 0.96 cm) via transpulmonary approach under CT guidance. Technical success was achieved in all cases immediately after the procedure. At 1-month follow-up, 65/69 (94.2%) patients had no residual disease (two patients were lost to follow-up). Pulmonary complications occurred in 26/71 (36.6%) sessions, and 15/26 (57.7%) were minor requiring no intervention. Pneumothorax occurred in 14/71 (19.7%) sessions, and the rate of major pneumothorax requiring chest tube was 8/71 (11.3%). Lesions on the left side of the liver (segments I-IV) and intraprocedural probe adiustment were found to be independent predictors of developing major pneumothorax (P = 0.007 and 0.028, respectively). There were no reported pulmonary complications at the 1-month follow-up. Conclusion: CT-guided transpulmonary MWA is safe and effective in treating hepatic malignancies. Although it is associated with the risk of developing pulmonary complications, patients underwent successful ablation of their hepatic malignancies without life-threatening complications and mortality.
- 20 January 2022
- Published by Scientific Scholar in Journal of Clinical Imaging Science
- Vol. 12, 1-7
Open AccessCT-guided microwave ablation of hepatic malignancies via transpulmonary approach without ancillary techniques
Objectives: The objectives of the study were to determine the safety and efficacy of computed tomography (CT)guided transpulmonary percutaneous microwave ablation (MWA) for hepatic malignancies without the use of ancillary techniques. Material and Methods: A retrospective review was performed on patients who underwent MWA for hepatic malignancy between January 2014 and February 2020 at a single tertiary center. Imaging was reviewed for each procedure to identify MWA showing transpleural transgression on CT scans. For these patients, demographics, ablation data, pulmonary complication rate, and predictors of pneumothorax were analyzed. Results: A total of 71 consecutive sessions (62.1 +/- 11.3 years, 79% of males) of MWA were performed to treat 71 tumors (1.90 +/- 0.96 cm) via transpulmonary approach under CT guidance. Technical success was achieved in all cases immediately after the procedure. At 1-month follow-up, 65/69 (94.2%) patients had no residual disease (two patients were lost to follow-up). Pulmonary complications occurred in 26/71 (36.6%) sessions, and 15/26 (57.7%) were minor requiring no intervention. Pneumothorax occurred in 14/71 (19.7%) sessions, and the rate of major pneumothorax requiring chest tube was 8/71 (11.3%). Lesions on the left side of the liver (segments I-IV) and intraprocedural probe adiustment were found to be independent predictors of developing major pneumothorax (P = 0.007 and 0.028, respectively). There were no reported pulmonary complications at the 1-month follow-up. Conclusion: CT-guided transpulmonary MWA is safe and effective in treating hepatic malignancies. Although it is associated with the risk of developing pulmonary complications, patients underwent successful ablation of their hepatic malignancies without life-threatening complications and mortality.
- Open Access
- 10 November 2021
- Published by Springer Nature in Cureus
- Vol. 13  (11)
Seurat Spleen: A Pathognomonic Sign in Angiography
Splenic injury commonly occurs following abdominal trauma and can result in severe complications and death if it goes unrecognized. The Seurat spleen is a term used to describe the angiographic appearance of splenic injury following blunt trauma, given its resemblance to the pointillistic artwork of French neo-impressionist Georges Seurat. We present a case of a 43-year-old man who presented following a motor vehicle collision and was found to have multiple punctate foci of contrast extravasation in the spleen consistent with the Seurat spleen angiographic sign. This angiographic pattern can be used as a pathognomonic sign to identify splenic injury, with early identification crucial to preventing further complications of the injury.
- 10 November 2021
- Published by Springer Nature in Cureus
- Vol. 13  (11)
Open AccessSeurat Spleen: A Pathognomonic Sign in Angiography
Splenic injury commonly occurs following abdominal trauma and can result in severe complications and death if it goes unrecognized. The Seurat spleen is a term used to describe the angiographic appearance of splenic injury following blunt trauma, given its resemblance to the pointillistic artwork of French neo-impressionist Georges Seurat. We present a case of a 43-year-old man who presented following a motor vehicle collision and was found to have multiple punctate foci of contrast extravasation in the spleen consistent with the Seurat spleen angiographic sign. This angiographic pattern can be used as a pathognomonic sign to identify splenic injury, with early identification crucial to preventing further complications of the injury.
- Open Access
- 1 October 2021
- Published by AME Publishing Company in Translational Gastroenterology and Hepatology
- Vol. 6, 59
Percutaneous microwave ablation of hepatic lesions near the heart
Percutaneous microwave ablation of hepatic lesions near the heart Sreeja Sanampudi, Qian Yu, Driss Raissi
- 1 October 2021
- Published by AME Publishing Company in Translational Gastroenterology and Hepatology
- Vol. 6, 59
Open AccessPercutaneous microwave ablation of hepatic lesions near the heart
Percutaneous microwave ablation of hepatic lesions near the heart Sreeja Sanampudi, Qian Yu, Driss Raissi
- Open Access
- 20 September 2021
- Published by Elsevier in Radiology Case Reports
- Vol. 16  (11) , 3593-3596
Rapid 3D reconstruction guided embolization for catastrophic bleeding following vacuum assisted breast biopsy; A case report and review of the literature
- 20 September 2021
- Published by Elsevier in Radiology Case Reports
- Vol. 16  (11) , 3593-3596
Open AccessRapid 3D reconstruction guided embolization for catastrophic bleeding following vacuum assisted breast biopsy; A case report and review of the literature